Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro Leukemia (2008) Tandutinib (MLN518; CT53518) is a promising quinazolinebased tyrosine kinase inhibitor that is currently in phase II clinical trails for treatment of acute myeloid leukaemia, where it targets the Flt-3 receptor. 1 Flt-3 is constitutively activated by internal tandem duplications in up to 30% of acute myelogenous leukemia patients, and a further 5-10% of patients have oncogenic mutations of Asp835 of the kinase domain.
2 Flt-3 is closely related to the KIT, PDGF and FMS receptors, and both KIT and PDGF receptors are targets of tandutinib with IC50 3 Here, we report that tandutinib inhibits the FMS receptor for macrophage-colony stimulating factor (M-CSF) with similar effectiveness and also inhibits osteoclastogenesis and macrophage colony formation in vitro. These findings imply that tandutinib may be useful in treating inflammatory and metastatic diseases, including bone metastasis where the FMS receptor is implicated. [4] [5] [6] The effect of tandutinib upon FMS was first assessed by using the murine haematopoietic cell line FDC-P1. This cell line is normally dependent upon IL-3 for growth, but M-CSF can also be used to stimulate the growth of cells that express recombinant FMS. Figure 1a shows that 1.6 mM tandutinib largely inhibited the growth of FDC-P1 cells expressing wild-type human FMS (FDc-fms). The IC50 for the inhibition of FDc-fms by tandutinib was calculated from Figure 1a as 0.4 mM. FDc-fms that were stimulated to grow using IL-3 instead of M-CSF were not inhibited by tandutinib, indicating that this drug inhibits FMS but not IL-3 signalling.
The growth of FDC-P1 cells expressing the oncogenic receptor FMS D802V was unaffected by tandutinib (Figure 1a) , which shows that mutation of Asp802 to Val of FMS confers resistance and indicates that tandutinib directly inhibits the wild-type FMS receptor expressed by FDC-P1 cells. This is in accordance with a previous report where the equivalent mutations of D835 of Flt-3 confer resistance to tandutinib. 7 As expected, tandutinib suppressed the transformed morphology of rodent fibroblasts caused by the expression of the oncogenic V-Fms receptor (Figures 1b and c) .
In conformation of the cell line results, Figure 1e shows that pretreatment with 0.25 mM tandutinib largely inhibited the phosphorylation of the mature form of human FMS expressed by Rat-2 fibroblasts in response to M-CSF (compare lanes 1 and 2). The high molecular weight smearing of the mature receptor that can be seen in lane 2 of Figure 1e is due to FMS ubiquitination. 8 Figure 1f shows that phosphorylation of the oncogenic FMS receptor FMSD802VY708F was resistant to tandutinib treatment. Unlike the wild-type receptor, both the mature and immature receptor forms of FMSD802VY708F are phosphorylated, and this occurs constitutively in the absence of M-CSF. 8 Similar results were obtained by in vitro kinase assays, which show that the kinase activity of wild-type FMS was inhibited by tandutinib and that FMSD802VY708F was resistant ( Figure 1g ). As expected, tandutinib also inhibited Erk and Akt phosphorylation in response to M-CSF (Supplementary Information). Figure 1d shows that tandutinib and imatinib inhibited colony formation of macrophages from mouse bone marrow cells with similar IC50 values of approximately 0.5 mM. This concentration of tandutinib also inhibited osteoclast formation from human mononuclear cells derived from mobilized peripheral blood and, as expected, inhibited bone resorption by human osteoclasts when cultured on dentine slices (Supplementary Information).
The concentration of tandutinib required to inhibit the FMS receptor, macrophage colony formation and osteoclastogenesis in vitro is less than the plasma trough levels of around 2 mM observed in patients who are treated with tandutinib. 1 This raises the possibility of some inhibitory effect of tandutinib upon these processes; however, it should be noted that the inhibitory effects of tandutinib and imatinib upon FMS are similar in vitro 8 and that imatinib is very well tolerated by patients.
Our results establish that tandutinib is an effective inhibitor of the FMS receptor, which is important for the production and activity of macrophages, osteoclasts and microglia. These cell types are implicated in a range of diseases including inflammation, metastasis and microglia-related neurodegenerative diseases. Consequently, tandutinib also has the potential to be developed as an inhibitor of the wide range of diseases that are known to be dependent upon FMS expression.
